Israel-based Theranica is developing the Nerivio Migra neurostimulation patch intended to treat migraine headache, which is currently under FDA review.
Funding in the round, which was initially announced in March, was led by aMoon and joined by Omron Ventures and all previous investors, including Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa.
“Being the world’s leading manufacturer and distributor of personal health and wellness products, we are excited to partner with a company that shares Omron Healthcare’s mission of improving people’s health at home through science and technology. Theranica’s forward-thinking approach of investing in science, building strong physician-community relationships and developing health products that center around the patients and their ability to improve their own well-being is the right model for today and the future,” Omron Ventures CEO Tomoko Inoue said in a prepared statement.
Theranica said that the newly raised funds will support mass production of its Nerivio Migra device and an eventual launch in the U.S., following the receipt of FDA clearance.
“Omron is a pioneer in innovative home medical equipment and therapeutic devices, and the recognition and commitment expressed by the decision of Ms. Inoue and her team to make this strategic investment is highly valued and appreciated by Theranica. Omron Healthcare has been a champion in enabling consumers to improve their health using convenient, affordable, easy to use health products. Aside from the financial resources Omron Ventures is committing to Theranica, we look forward to learning from such a healthcare market leader,” co-founder & CEO Alon Ironi said in a press release.